See other companies on Welcome to the Jungle
Unlearn.AI
Generative machine learning methods for medicine
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Machine Learning
- eCommerce
- Science
- Yerba Buena, San Francisco, CA
Jump to section
Company mission
To advance artificial intelligence to eliminate trial and error in medicine.
28% employee growth in 12 months
Our take
Clinical trials supporting the development of new drugs typically drag out for a number of years. With the root of this problem being the lack of qualified participants, especially when drugs reach critical phase 3 studies, which often require hundreds or thousands of participants to test the investigational drug.
Machine learning generative AI startup, Unlearn.AI, is looking to tackle this challenge and transform the way clinical trials are performed. The company specializes in clinical trial optimization through its proprietary technology, called the "Digital Twin", which creates a virtual replica of a patient population in order to simulate the effects of different treatments. Through this approach, researchers are able to run clinical trials with smaller sample sizes, reducing the time and costs associated with traditional clinical trials.
Since its inception in 2017, Unlearn.AI has worked with a number of pharmaceutical companies as well as academic institutions in order to improve clinical trial designs and accelerate drug development efforts. With a bright future on the horizon for the AI startup, Unlearn.AI has the potential to revolutionize healthcare, diagnostics, and treatment.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- 100% employer-covered medical, dental, and vision insurance for you and your family
- Company-paid life insurance, AD&D insurance, short-term/long-term disability insurance
- 401k plan with generous matching
- Paid parental leave
- Professional development budget to attend conferences, workshops, classes, and more
Funding (last 2 of 6 rounds)
Feb 2024
$50m
SERIES C
Mar 2023
$15m
LATE VC
Total funding: $130.7m
This company has top investors
Leadership
Charles Fisher
(CEO)Graduated from Harvard University with a Ph.D. in Biophysics. Previously worked as a Machine Learning Engineer at Leap Motion, as well as a Principal Scientist at Pfizer.